A mechanistic and structural analysis of the inhibition of the 90-kDa heat shock protein by the benzoquinone and hydroquinone ansamycins

Molecular Pharmacology

Volumn 79, Issue 5, 2011, Pages 823-832

  Reigan, Philip ^a   Siegel, David ^a   Guo, Wenchang ^a   Ross, David ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANSAMYCIN DERIVATIVE; BENZOQUINONE; FLAVINE MONONUCLEOTIDE REDUCTASE; HEAT SHOCK PROTEIN 90; HYDROQUINONE;

ARTICLE; CIS ISOMER; CIS TRANS ISOMERISM; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; ISOMERIZATION; MOLECULAR DOCKING; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN STRUCTURE; STRUCTURE ANALYSIS; TRANS ISOMER;

BENZOQUINONES; CATALYTIC DOMAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HSP90 HEAT-SHOCK PROTEINS; HYDROQUINONES; LACTAMS, MACROCYCLIC; MASS SPECTROMETRY; MODELS, MOLECULAR; NAD(P)H DEHYDROGENASE (QUINONE); PROTEIN CONFORMATION;

EID: 79955042825     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.070086     Document Type: Article

References (40)

1. Beall HD, Mulcahy RT, Siegel D, Traver RD, Gibson NW, and Ross D (1994) Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorases. Cancer Res 54:3196-3201. (Pubitemid 24208928)
2. Bouckaert J, Dewallef Y, Poortmans F, Wyns L, and Loris R (2000) The structural features of concanavalin A governing non-proline peptide isomerization. J Biol Chem 275:19778-19787. (Pubitemid 30441578)
3. Brooks BR, Brooks CL, 3rd, Mackerell AD, Jr., Nilsson L, Petrella RJ, Roux B, Won Y, Archontis G, Bartels C, Boresch S, Caflisch A, Caves L, Cui Q, Dinner AR, Feig M, Fischer S, Gao J, Hodoscek M, Im W, Kuczera K, Lazaridis T, Ma J, Ovchinnikov V, Paci E, Pastor RW, Post CB, Pu JZ, Schaefer M, Tidor B, Venable RM, Woodcock HL, Wu X, Yang W, York DM, and Karplus M (2009) CHARMM: the biomolecular simulation program. J Comput Chem 30:1545-1614.
4. Cavelier G and Amzel LM (2001) Mechanism of NAD (P) H:quinone reductase: Ab initio studies of reduced flavin. Proteins 43:420-432. (Pubitemid 32476438)
5. Chiosis G, Huezo H, Rosen N, Mimnaugh E, Whitesell L, and Neckers L (2003) 17AAG: low target binding affinity and potent cell activity-finding an explanation. Mol Cancer Ther 2:123-129.
6. Chiosis G and Neckers L (2006) Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. ACS Chem Biol 1:279-284.
7. Clarke ED, Wardman P, and Wilson I (1984) Cis-trans isomerization of the (5-nitro-2-furyl) acrylamide, AF-2, initiated by ascorbate, glutathione, F (II) and OH-. Biochem Pharmacol 33:83-87.
8. Cysyk RL, Parker RJ, Barchi JJ, Jr., Steeg PS, Hartman NR, and Strong JM (2006) Reaction of geldanamycin and C17-substituted analogues with glutathione: product identifications and pharmacological implications. Chem Res v19:376-381.
9. Duerfeldt AS, Brandt GE, and Blagg BS (2009) Design, synthesis, and biological evaluation of conformationally constrained cis-amide Hsp90 inhibitors. Org Lett 11:2353-2356.
10. Egorin MJ, Rosen DM, Wolff JH, Callery PS, Musser SM, and Eiseman JL (1998) Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 58:2385-2396.
11. Feig M, Onufriev A, Lee MS, Im W, Case DA, and Brooks CL 3rd (2004) Performance comparison of generalized born and Poisson methods in the calculation of electrostatic solvation energies for protein structures. J Comput Chem 25:265-284.
12. Gooljarsingh LT, Fernandes C, Yan K, Zhang H, Grooms M, Johanson K, Sinnamon RH, Kirkpatrick RB, Kerrigan J, Lewis T, et al. (2006) A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues. Proc Natl Acad Sci USA 103:7625-7630.
13. Guo W, Reigan P, Siegel D, and Ross D (2008) Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action. Drug Metab Dispos 36:2050-2057.
14. Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, and Ross D (2005) Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD (P) H: quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res 65:10006-10015. (Pubitemid 41541482)
15. Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, and Ross D (2006) The bioreduction of a series of benzoquinone ansamycins by NAD (P) H:quinone oxidoreductase 1 to more potent heat shock protein 90 inhibitors, the hydroquinone ansamycins. Mol Pharmacol 70:1194-1203. (Pubitemid 44435970)
16. Hur S and Bruice TC (2002) The mechanism of cis-trans isomerization of prolyl peptides by cyclophilin. J Am Chem Soc 124:7303-7313. (Pubitemid 34670439)
17. Jez JM, Chen JC, Rastelli G, Stroud RM, and Santi DV (2003) Crystal structure and molecular modeling of 17-DMAG in complex with human Hsp90. Chem Biol 10:361-368. (Pubitemid 36516654)
18. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, and Burrows FJ (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425:407-410. (Pubitemid 37187270)
19. Kelland LR, Sharp SY, Rogers PM, Myers TG, and Workman P (1999) DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 91:1940-1949.
20. Koska J, Spassov VZ, Maynard AJ, Yan L, Austin N, Flook PK, and Venkatachalam CM (2008) Fully automated molecular mechanics based induced fit protein-ligand docking method. J Chem Inf Model 48:1965-1973.
21. Lang W, Caldwell GW, Li J, Leo GC, Jones WJ, and Masucci JA (2007) Biotransformation of geldanamycin and 17-allylamino-17-demethoxygeldanamycin by human liver microsomes: reductive versus oxidative metabolism and implications. Drug Metab Dispos 35:21-29. (Pubitemid 46036472)
22. Lee YS, Marcu MG, and Neckers L (2004) Quantum chemical calculations and mutational analysis suggest heat shock protein 90 catalyzes trans-cis isomerization of geldanamycin. Chem Biol 11:991-998. (Pubitemid 38991793)
23. Li R, Bianchet MA, Talalay P, and Amzel LM (1995) The three-dimensional structure of NAD (P) H:quinone reductase, a flavoprotein involved in cancer chemoprotection and chemotherapy: mechanism of the two-electron reduction. Proc Natl Acad Sci USA 92:8846-8850.
24. Maloney A and Workman P (2002) HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2:3-24. (Pubitemid 34462457)
25. Onuoha SC, Mukund SR, Coulstock ET, Sengerová B, Shaw J, McLaughlin SH, and Jackson SE (2007) Mechanistic studies on Hsp90 inhibition by ansamycin derivatives. J Mol Biol 372:287-297. (Pubitemid 47267952)
26. Pappenberger G, Aygün H, Engels JW, Reimer U, Fischer G, and Kiefhaber T (2001) Nonprolyl cis peptide bonds in unfolded proteins cause complex folding kinetics. Nat Struct Biol8:452-458. (Pubitemid 32381295)
27. Pearl LH and Prodromou C (2000) Structure and in vivo function of Hsp90. Curr Opin Struct Biol 10:46-51. (Pubitemid 30099326)
28. Pearl LH and Prodromou C (2006) Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 75:271-294. (Pubitemid 44118034)
29. Reigan P, Colucci MA, Siegel D, Chilloux A, Moody CJ, and Ross D (2007) Development of indolequinone mechanism-based inhibitors of NAD (P) H:quinone oxidoreductase 1 (NQO1): NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells. Biochemistry 46:5941-5950. (Pubitemid 46799156)
30. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, and Pearl LH (1999) Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 42:260-266. (Pubitemid 29069861)
31. Rooseboom M, Commandeur JN, and Vermeulen NP (2004) Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev 56:53-102. (Pubitemid 38314580)
32. Ross D (2004) Quinone reductases multitasking in the metabolic world. Drug Metab Rev 36:639-654. (Pubitemid 39453067)
33. Rowlands MG, Newbatt YM, Prodromou C, Pearl LH, Workman P, and Aherne W (2004) High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Anal Biochem 327:176-183. (Pubitemid 38402186)
34. Schiene-Fischer C, Habazettl J, Schmid FX, and Fischer G (2002) The hsp70 chaperone DnaK is a secondary amide peptide bond cis-trans isomerase. Nat Struct Biol 9:419-424. (Pubitemid 34568785)
35. Schmid FX (1993) Prolyl isomerase: enzymatic catalysis of slow protein-folding reactions. Annu Rev Biophys Biomol Struct 22:123-142.
36. Schnur R and Corman ML (1994) Tandem [3,3]-sigmatropic rearrangements in an ansamycin-stereospecific conversion of an (S)-allylic alcohol to an (S)-allylic amine derivative. J Org Chem 59:2581-2584.
37. Siegel D and Ross D (2000) Immunodetection of NAD (P) H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic Biol 29:246-253.
38. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, and Pavletich NP (1997) Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89:239-250. (Pubitemid 27199896)
39. Thepchatri P, Eliseo T, Cicero DO, Myles D, and Snyder JP (2007) Relationship among ligand conformations in solution, in the solid state, and at the Hsp90 binding site: geldanamycin and radicicol. J Am Chem Soc 129:3127-3134. (Pubitemid 46449344)
40. Winski SL, Faig M, Bianchet MA, Siegel D, Swann E, Fung K, Duncan MW, Moody CJ, Amzel LM, and Ross D (2001) Characterization of a mechanism-based inhibitor of NAD (P) H:quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass approaches. Biochemistry 40:15135-15142. (Pubitemid 33151928)